Poor response to daratumumab and carfilzomib in newly diagnosed anaplastic multiple myeloma

J Clin Exp Hematop. 2020;60(1):17-20. doi: 10.3960/jslrt.19031.

Authors

Masuho Saburi¹, Masao Ogata², Yasuhiro Soga³, Yoshiyuki Kondo⁴, Ryo Kurimoto¹, Kazuhito Itani¹, Kazuhiro Kohno¹, Hiroki Uchida⁵, Toshiyuki Nakayama¹

Affiliations

¹ Department of Hematology, Oita Kouseiren Tsurumi Hospital, Oita, Japan.
² Department of Hematology, Oita University Hospital, Oita, Japan.
³ Department of Clinical Laboratory, Oita Kouseiren Tsurumi Hospital, Oita, Japan.
⁴ Department of Diagnostic Pathology, Oita Kouseiren Tsurumi Hospital, Oita, Japan.
⁵ Department of Nephrology, Oita Kouseiren Tsurumi Hospital, Oita, Japan.

No abstract available

Keywords: anaplastic multiple myeloma; carfilzomib; daratumumab.

Publication types

Case Reports

MeSH terms

Aged
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents / therapeutic use*
Bone Marrow / drug effects
Bone Marrow / pathology
Female
Humans
Multiple Myeloma / blood
Multiple Myeloma / diagnosis
Multiple Myeloma / drug therapy*
Oligopeptides / therapeutic use*
Plasma Cells / drug effects
Plasma Cells / pathology
Treatment Outcome

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Oligopeptides
daratumumab
carfilzomib